Pharmaceutical

FDA expands approval of Dupixent for eosinophilic esophagitis in children

Regeneron and Sanofi’s blockbuster anti-inflammatory drug generated global sales of $8.68bn in 2022.

Jan 27, 2024 - 18:00
FDA expands approval of Dupixent for eosinophilic esophagitis in children
Regeneron and Sanofi’s blockbuster anti-inflammatory drug generated global sales of $8.68bn in 2022.
Read the original article

Tags:

Previous Article

Atossa Therapeutics progresses Phase II preventative breast cancer therapy

Next Article

Travere signs $120m licensing deal with Renalys for sparsentan in Asia

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

BeiGene secures accelerated FDA approval for follicular lymphoma treatment

BeiGene secures accelerated FDA approval for follicular...

Mar 9, 2024

Formosa and Tabuk sign deal for FDA-approved ophthalmic suspension

Formosa and Tabuk sign deal for FDA-approved ophthalmic...

May 11, 2024

Apple and Anthem’s experimental asthma app shows early promise but its future is uncertain

Apple and Anthem’s experimental asthma app shows early ...

Nov 9, 2023